Back to Authors

Patel, Krishna

https://orcid.org/0000-0002-4986-0955

Mayo Clinic

Institute of Bioinformatics

Citations 5

MicroRNA Expression Profile in Early-Stage Breast Cancers
Patel, Krishna , Rao, Deva Magendhra , Sundersingh, Shirley , Sridevi, Velusami , Rajkumar, Thangarajan , Nair, B J Bipin , Pandey, Akhilesh , Chatterjee, Aditi , Mani, Samson , Gowda, Harsha , Rao, Arunagiri Kuha Deva Magendhra , Nair, Bipin , Pandey, Akhilesh , Gowda, Harsha

MicroRNA | October 19, 2023 | Volume: 13 | Issue: 1 | Pages: 71-81

10.2174/0122115366256479231003064842 Get It

Background:: Breast cancer is one of the leading causes of cancer deaths in women. Early diagnosis offers the best hope for a cure. Ductal carcinoma in situ is considered a precursor of invasive ductal carcinoma of the breast. In this study, we carried out microRNA sequencing from 7 ductal carcinoma in situ (DCIS), 6 infiltrating ductal carcinomas (IDC Stage IIA) with paired normal, and 5 unpaired normal breast tissue samples. We identified 76 miRNAs that were differentially expressed in DCIS and IDC. Methods:: Additionally, we provide preliminary evidence of miR-365b-3p and miR-7-1-3p being overexpressed, and miR-6507-5p, miR-487b-3p, and miR-654-3p being downregulated in DCIS relative to normal breast tissue. We also identified a miRNA miR-766-3p that was overexpressed in early-stage IDCs. The overexpression of miR-301a-3p in DCIS and IDC was confirmed in 32 independent breast cancer tissue samples. Results:: Higher expression of miR-301a-3p is associated with poor overall survival in The Can-cer Genome Atlas Breast Cancer (TCGA-BRCA) dataset, indicating that it may be associated with DCIS at high risk of progressing to IDC and warrants deeper investigation. Conclusion:: We also analyzed competing endogenous networks associated with differentially expressed miRNAs and identified LRRC75A-AS1 and MAGI2-AS3 as lncRNAs that potentially play an important role in early-stage breast cancers.
Molecular Characterization of Esophageal Squamous Cell Carcinoma Using Quantitative Proteomics
Mangalaparthi, Kiran K. , Patel, Krishna , Khan, Aafaque Ahmad , Kumar, Rekha V. , Prasad, Thottethodi Subrahmanya Keshava , Sidransky, David , Chatterjee, Aditi , Pandey, Akhilesh , Gowda, Harsha , Prasad, Thottethodi Subrahmanya Keshav , Pandey, Akhilesh , Gowda, Harsha , Nair, Bipin G.

Cancers | June 26, 2023 | Volume: 15 | Issue: 13 | Pages: 3302

10.3390/cancers15133302 Get It

Esophageal squamous cell carcinoma (ESCC) is a heterogeneous cancer associated with a poor prognosis in advanced stages. In India, it is the sixth most common cause of cancer-related mortality. In this study, we employed high-resolution mass spectrometry-based quantitative proteomics to characterize the differential protein expression pattern associated with ESCC. We identified several differentially expressed proteins including PDPN, TOP2A, POSTN and MMP2 that were overexpressed in ESCC. In addition, we identified downregulation of esophagus tissue-enriched proteins such as SLURP1, PADI1, CSTA, small proline-rich proteins such as SPRR3, SPRR2A, SPRR1A, KRT4, and KRT13, involved in squamous cell differentiation. We identified several overexpressed proteins mapped to the 3q24-29 chromosomal region, aligning with CNV alterations in this region reported in several published studies. Among these, we identified overexpression of SOX2, TP63, IGF2BP2 and RNF13 that are encoded by genes in the 3q26 region. Functional enrichment analysis revealed proteins involved in cell cycle pathways, DNA replication, spliceosome, and DNA repair pathways. We identified the overexpression of multiple proteins that play a major role in alleviating ER stress, including SYVN1 and SEL1L. The SYVN1/SEL1L complex is an essential part of the ER quality control machinery clearing misfolded proteins from the ER. SYVN1 is an E3 ubiquitin ligase that ubiquitinates ER-resident proteins. Interestingly, there are also other non-canonical substrates of SYVN1 which are known to play a crucial role in tumor progression. Thus, SYVN1 could be a potential therapeutic target in ESCC.
Urinary glycoproteomic profiling of non-muscle invasive and muscle invasive bladder carcinoma patients reveals distinct N-glycosylation pattern of CD44, MGAM, and GINM1
George, Irene A., Deb, Barnali, Jain, Ankit , Nayak, Brusabhanu , Seth, Amlesh , Pandey, Akhilesh , Kumar, Prashant , Pandey, Akhilesh , Kumar, Prashant , Sathe, Gajanan , Patel, Krishna , Karmakar, Subhradip

Oncotarget | August 25, 2020 | Volume: 11 | Issue: 34 | Pages: 3244-3255

10.18632/oncotarget.27696 Get It

Family-Based Next-Generation Sequencing Study Identifies an IL2RG Variant in an Infant with Primary Immunodeficiency
Bandari, Aravind K. , Bhat, Sunil, Archana, MV, Yadavalli, Sunita, Rajagopalan, Pavithra, Madugundu, Anil K. , Madkaikar, Manisha , Reddy, Kavita S., Pandey, Akhilesh , Pandey, Akhilesh , Pandey, Akhilesh , Patel, Krishna , Reddy, Kavita, Muthusamy, Babylakshmi

OMICS: A Journal of Integrative Biology | May 17, 2019 | Volume: 23 | Issue: 5 | Pages: 285-290

10.1089/omi.2018.0196 Get It

Abstract Primary immunodeficiencies (PIDs) are a rare and heterogeneous group of inherited genetic disorders that are characterized by an absent or impaired immune system. In this report, we describe the use of next-generation sequencing to investigate a male infant with clinical and immunological manifestations suggestive of a PID. Whole-exome sequencing of the infant along with his parents revealed a novel nucleotide variant (cytosine to adenine substitution at nucleotide position 252) in the coding region of the interleukin 2 receptor subunit gamma ( IL2RG ) gene. The mother was found to be a carrier. These findings are consistent with a diagnosis of X-linked severe combined immunodeficiency and represent the first such reported mutation in an Indian family. This mutation leads to an asparagine to lysine substitution ( p.Asn84Lys ) located in the extracellular domain of IL2RG, which is predicted to be pathogenic. Our study demonstrates the power of next-generation sequencing in identifying potential causative mutations to enable accurate clinical diagnosis, prenatal screening, and carrier female detection in PID patients. We believe that this approach, which is not a current routine in clinical practice, will become a mainstream component of individualized medicine in the near future.
Identification of lnc RNA s associated with early‐stage breast cancer and their prognostic implications
Rao, Arunagiri Kuha Deva Magendhra , Patel, Krishna , Jyothiraj, Suneetha Korivi, Meenakumari, Balaiah, Sundersingh, Shirley , Sridevi, Velusami , Rajkumar, Thangarajan , Pandey, Akhilesh , Chatterjee, Aditi , Mani, Samson , Pandey, Akhilesh , Gowda, Harsha

Molecular Oncology | April 8, 2019 | Volume: 13 | Issue: 6 | Pages: 1342-1355

10.1002/1878-0261.12489 Get It

Breast cancer is the most common malignancy among women, with the highest incidence rate worldwide. Dysregulation of long noncoding RNA s during the preliminary stages of breast carcinogenesis is poorly understood. In this study, we performed RNA sequencing to identify long noncoding RNA expression profiles associated with early‐stage breast cancer. RNA sequencing was performed on six invasive ductal carcinoma (IDC) tissues along with paired normal tissue samples, seven ductal carcinoma in situ tissues, and five apparently normal breast tissues. We identified 375 differentially expressed lncRNAs (DElncRNAs) in IDC tissues compared to paired normal tissues. Antisense transcripts (~ 58%) were the largest subtype among DE lnc RNA s. About 20% of the 375 DE lnc RNA s were supported by typical split readings leveraging their detection confidence. Validation was performed in n = 52 IDC and paired normal tissue by qRT ‐ PCR for the identified targets ( ADAMTS 9‐ AS 2, EPB 41L4A‐ AS 1, WDFY 3‐ AS 2, RP 11‐295M3.4, RP 11‐161M6.2, RP 11‐490M8.1, CTB ‐92J24.3, and FAM 83H‐ AS 1). We evaluated the prognostic significance of DE lnc RNA s based on TCGA datasets and report that overexpression of FAM 83H‐ AS 1 was associated with patient poor survival. We confirmed that the downregulation of ADAMTS 9‐ AS 2 in breast cancer was due to promoter hypermethylation through in vitro silencing experiments and pyrosequencing.